Lanthionine synthetase C-like 2-based therapeutics

A method of treating a condition in an animal with a compound, the method comprising administering an effective amount of the compound to the animal, wherein:

• the condition is selected from the group consisting of an infectious disease, an autoimmune disease, diabetes, and a chronic inflammatory disease;
• and
• the compound is a compound comprising formula A-B-C or a pharmaceutically acceptable salt or ester thereof, wherein:
• A7, A8, A9, A10, A11, A12, A13, and A14 are each independently selected from CH, CR18, and N;
• A15, A16, A17, A18, A19, and A20 are each independently selected from CH, CR19, N, NR20, O, and S, with the proviso that one and only one of A15, A16, and A17 is NR20, O, or S and one and only one of A18, A19, and A20 is NR20, O, or S;
• R18 and R19 are each independently selected from C1-C6 alkyl;
• C1-C6 dialkylamino, wherein each C1-C6 alkyl is independently selected;
• —NH2;
• alkylamino;
• heterocycloalkyl;
• and substituted heterocycloalkyl, wherein the substituted heterocycloalkyl is substituted with one to two substituents independently selected from the group consisting of:
• —C(O)O(C1-C6 alkyl) and C1-C6 alkyl;
• wherein in compounds with more than one CR18 each R18 is independently selected, and in compounds with more than one CR19 each R19 is independently selected;
• and
• R20 is C1-C6 alkyl.